Last updated: September 3, 2026
Cevimeline hydrochloride is a small, off-patent oral muscarinic agonist used primarily to treat dry mouth associated with Sjögren's syndrome. Its commercial value is limited by a narrow indication and modest market size, but the product has practical reformulation opportunities. The strongest opportunities are differentiated oral dosage forms, excipient substitutions that improve tolerability or supply resilience, and patient-friendly delivery systems for individuals with swallowing difficulty or severe xerostomia.
What is the commercial status of cevimeline hydrochloride?
Cevimeline hydrochloride is marketed in the United States as Evoxac, a 30 mg oral capsule. The FDA approved Evoxac in 2000 for the treatment of symptoms of dry mouth in patients with Sjögren's syndrome.[1]
| Attribute |
Cevimeline hydrochloride |
| Active ingredient |
Cevimeline hydrochloride |
| Pharmacologic class |
Muscarinic cholinergic agonist |
| Primary indication |
Dry mouth associated with Sjögren's syndrome |
| US reference product |
Evoxac |
| Dosage form |
Immediate-release capsule |
| Common strength |
30 mg |
| Original US approval |
2000 |
| Reference applicant |
Daiichi Sankyo, formerly Daiichi Pharmaceutical |
| Administration |
Oral, typically three times daily |
| Main adverse-effect concerns |
Sweating, gastrointestinal effects, visual disturbance, cardiovascular and pulmonary contraindications |
| Regulatory pathway for competitors |
Abbreviated New Drug Application, or ANDA |
The label recommends 30 mg three times daily, although dose reduction to 30 mg twice daily may be appropriate for patients with tolerability issues.[1] The dosing frequency creates a clear formulation opportunity: a product that maintains exposure with fewer daily doses could have greater commercial value than a conventional excipient substitution.
What patents protect cevimeline hydrochloride?
Cevimeline hydrochloride is no longer primarily protected by active composition-of-matter exclusivity in the United States. The original product’s commercial protection was based on older small-molecule and product patents, regulatory exclusivity, and brand positioning. Those barriers have largely expired.
The relevant current IP question is not whether the cevimeline molecule remains protected. It is whether a competitor can obtain protection for a new formulation, dosage regimen, manufacturing process, or device-enabled delivery system.
Patent protection and Orange Book status
The Orange Book records patents and exclusivity associated with approved drug products. For an older product such as Evoxac, the commercial relevance of any remaining listing must be assessed against:
- Patent expiration date.
- Whether the patent claims the active ingredient, formulation, method of use, or manufacturing process.
- Whether the listed patent is subject to a Paragraph IV challenge.
- Whether the patent is still enforceable against a proposed ANDA product.
- Whether the proposed generic design can avoid infringement.
An ANDA applicant that seeks approval before expiration of a listed patent can submit a Paragraph IV certification. The NDA holder may file patent litigation within 45 days, triggering a statutory stay of FDA approval for up to 30 months under the Hatch-Waxman framework.[2]
No biosimilar pathway applies. Cevimeline hydrochloride is a chemically synthesized small molecule, so competitors file ANDAs rather than abbreviated biologics license applications.
Patent expiration and generic entry risk
The core generic-entry risk is high because:
- Cevimeline hydrochloride is a small molecule.
- The active ingredient is administered in a conventional oral capsule.
- The reference product has been marketed for more than two decades.
- The product does not depend on a complex biologic manufacturing platform.
- Generic applicants can generally rely on conventional bioequivalence testing.
The principal barriers are commercial rather than foundational patent barriers. These include limited market size, manufacturing economics, controlled supply of pharmaceutical-grade excipients, and the need to demonstrate adequate product stability.
How many patents cover cevimeline hydrochloride?
The number of commercially meaningful patents is likely low compared with newer specialty drugs. The original active-ingredient and product claims do not provide a durable current barrier. Any relevant protection is more likely to arise from:
- New oral dosage forms.
- Modified-release formulations.
- Taste-masked or orally disintegrating products.
- Combination products.
- New dosing schedules.
- Manufacturing processes with improved yield or impurity control.
- Drug-device combinations.
- Formulations designed for patients with severe swallowing or salivary dysfunction.
A patent estate built around excipients alone is usually weak unless the claims require a specific composition, concentration range, manufacturing sequence, or performance result. Generic applicants can often avoid narrow excipient claims by substituting functionally equivalent materials.
What excipients are used in cevimeline capsules?
The reference product is an immediate-release hard capsule. Public product labeling identifies conventional oral solid dosage excipients, including lactose, starch, magnesium stearate, and capsule-shell components such as gelatin and colorants.[1,3]
Exact inactive ingredients may vary by manufacturer and strength. Generic cevimeline products do not need to use the same excipients as Evoxac. They must meet applicable pharmaceutical quality, stability, dissolution, and bioequivalence requirements.
Functional role of the principal excipients
| Excipient category |
Likely function in cevimeline capsules |
Commercial relevance |
| Lactose or other diluent |
Provides capsule fill mass and improves manufacturability |
Cost, lactose intolerance, supply continuity |
| Starch |
Filler, disintegrant, or processing aid |
Supports rapid capsule opening and dissolution |
| Magnesium stearate |
Lubricant |
Excess levels can slow wetting and dissolution |
| Gelatin |
Hard-capsule shell |
Animal-origin, religious, dietary, and supply considerations |
| Titanium dioxide or colorants |
Capsule identification and appearance |
Regulatory scrutiny and market-specific restrictions |
| Printing ink |
Product identification |
Low technical value but relevant to capsule differentiation |
The formulation is not technically complex. That reduces development risk but also limits the value of a simple "same capsule, different excipients" strategy.
What excipient strategy is most attractive for cevimeline?
The best strategy depends on the target segment. A generic manufacturer seeking the lowest development cost should use a conventional immediate-release capsule with a well-characterized filler, disintegrant, and lubricant system. A specialty manufacturer should pursue a differentiated dosage form.
Strategy 1: Lactose-free immediate-release capsule
A lactose-free product could address patients who avoid lactose or who experience gastrointestinal sensitivity. Mannitol, microcrystalline cellulose, dibasic calcium phosphate, or pregelatinized starch could replace lactose, subject to compatibility and dissolution testing.
The commercial benefit is likely modest because lactose-free positioning alone does not create strong clinical differentiation. It can, however, support institutional procurement, international registration, and patient-specific product selection.
Strategy 2: Plant-based capsule shell
Hydroxypropyl methylcellulose capsules could replace gelatin. The value proposition includes:
- Vegetarian and vegan positioning.
- Reduced dependence on animal-derived materials.
- Simplified acceptance in certain religious or institutional markets.
- Potentially improved performance under selected humidity conditions.
The primary technical issue is fill-shell interaction. HPMC capsules can have different moisture behavior and dissolution characteristics from gelatin capsules. The formulation must maintain rapid release across physiological pH conditions and remain stable under accelerated storage.
Strategy 3: Orally disintegrating tablet
An orally disintegrating tablet, or ODT, is a logical development path because the target population has impaired salivary function. A conventional ODT design could use mannitol for mouthfeel, crospovidone or croscarmellose sodium for rapid disintegration, a low level of lubricant, and a taste-masking system.
The main problem is taste. Cevimeline hydrochloride is a pharmacologically active salt and may produce an unpleasant oral sensation. Taste masking could use:
- Polymer coating.
- Ion-exchange resin complexes.
- Lipid-based coating.
- Spray-dried matrix particles.
- Flavor and sweetener systems.
- Multiparticulate encapsulation.
An ODT would not automatically improve therapy. The active ingredient may stimulate cholinergic effects throughout the body, so a more convenient dosage form would need to preserve safety and avoid encouraging excessive dosing.
Strategy 4: Buccal or sublingual delivery
A buccal product could theoretically deliver cevimeline directly through the oral mucosa. This strategy has a strong disease-state rationale because patients with Sjögren's syndrome often have difficulty swallowing and severe oral dryness.
The development risks are substantial:
- Low and variable saliva volume.
- Limited residence time.
- Mucosal irritation.
- Dose uniformity at low tablet mass.
- Taste exposure.
- Potentially greater local cholinergic effects.
- Uncertain relationship between local delivery and systemic efficacy.
A mucoadhesive buccal film or tablet could be patentable, but clinical and regulatory development would be more demanding than an ANDA for a conventional capsule.
Strategy 5: Modified-release formulation
Cevimeline is commonly administered three times daily. A sustained-release product could reduce dosing frequency and improve adherence. Potential excipient systems include hydrophilic matrix polymers, coated multiparticulates, osmotic systems, and lipid matrices.
The opportunity is commercially more meaningful than a simple excipient replacement because dosing convenience can support a branded 505(b)(2) strategy. The development program would need pharmacokinetic, dose-proportionality, food-effect, and safety data. A modified-release product would also face competition from low-cost immediate-release generics.
What formulations are protected by cevimeline patents?
Any commercially defensible formulation patent would need claims tied to measurable performance or a defined composition. Examples include:
- A cevimeline hydrochloride extended-release matrix with a specified dissolution profile.
- An ODT containing a defined disintegration time and taste-masking system.
- A buccal film with a specified residence time and release rate.
- A low-moisture capsule formulation with defined impurity limits.
- A formulation that reduces degradation under high humidity.
- A multiparticulate dosage form that separates cevimeline from incompatible excipients.
- A fixed-dose product combining cevimeline with another agent used in Sjögren's syndrome.
Generic substitution risk is highest for broad claims covering ordinary fillers, binders, and lubricants. Patent strength improves when claims connect excipient selection to a demonstrated technical result.
How strong is the patent estate for cevimeline hydrochloride?
The legacy patent estate is weak as a barrier to conventional generic capsules. A new formulation estate could be moderate if it satisfies four conditions:
- The product has a clinically relevant advantage.
- The claims require a specific formulation architecture.
- The formulation produces a reproducible dissolution or pharmacokinetic profile.
- The product is commercially differentiated enough to justify litigation or licensing.
A formulation patent based only on substituting lactose with mannitol would usually have limited blocking power. A formulation that reduces dosing frequency, enables administration without water, or improves stability in hot and humid markets would have greater commercial value.
What is the FDA regulatory status of cevimeline hydrochloride?
Evoxac is an FDA-approved prescription drug. A conventional generic capsule would generally use the ANDA pathway and demonstrate pharmaceutical equivalence and bioequivalence to the reference product.[1,2]
A substantially changed product may require a 505(b)(2) application rather than an ANDA. This could apply to:
- Modified-release dosage forms.
- New routes of administration.
- New strengths or dosing regimens.
- Products with clinical benefits not established by conventional bioequivalence.
- Certain combination products.
FDA approval does not establish commercial exclusivity for every reformulation. Exclusivity depends on the application type, the data package, and applicable statutory provisions.
Which companies are challenging the cevimeline market?
The market is open to generic competition because the reference product is mature and the molecule is chemically straightforward. Generic applicants may include established manufacturers of specialty oral solids and smaller companies that license or acquire ANDA assets.
The commercial competitive set includes:
- Brand Evoxac.
- Authorized or conventional generic cevimeline capsules.
- Compounded saliva substitutes and oral moisturizers.
- Pilocarpine products, particularly Salagen.
- Nonprescription dry-mouth products, including gels, sprays, lozenges, and rinses.
- Emerging therapies directed at Sjögren's syndrome rather than symptomatic saliva stimulation.
Generic competition does not eliminate opportunity. It changes the value proposition from molecule ownership to product design, distribution, adherence, and manufacturing cost.
How does cevimeline compare with pilocarpine?
Cevimeline and pilocarpine are both oral secretagogues used for xerostomia, but their competitive profiles differ.
| Factor |
Cevimeline hydrochloride |
Pilocarpine |
| Primary commercial brand |
Evoxac |
Salagen |
| Typical use |
Sjögren's-associated dry mouth |
Xerostomia, including radiation-related cases and Sjögren's syndrome |
| Common oral dosage form |
Immediate-release capsule |
Immediate-release tablet |
| Dosing burden |
Often three times daily |
Often multiple daily doses |
| Formulation opportunity |
ODT, modified release, buccal delivery |
Similar, but broader established market |
| Generic risk |
High |
High |
| Differentiation route |
Better tolerability, convenience, lactose-free or ODT product |
Broader indication and established tablet market |
Cevimeline may offer a focused specialty opportunity in Sjögren's syndrome. Pilocarpine may have greater market depth because of broader clinical use and higher physician familiarity.
What generic launch scenarios exist for cevimeline?
Conventional generic capsule
This is the lowest-risk launch model. The manufacturer uses an immediate-release capsule with standard excipients and competes primarily on price, supply reliability, and wholesaler access.
Premium generic
A premium generic can use a lactose-free capsule, HPMC shell, improved packaging, or a lower-cost manufacturing process. The product remains close enough to the reference product for an ANDA strategy but adds procurement and patient-selection benefits.
505(b)(2) reformulation
An ODT, modified-release product, or alternative route may support branded pricing and formulation patents. The clinical development burden is higher, but the product could compete on adherence rather than price.
Geographic specialty launch
Markets with high humidity, limited cold-chain infrastructure, or large Sjögren's patient populations may reward moisture-resistant packaging and robust capsule stability. Regional opportunities include blister packaging, desiccant systems, and excipient systems with reduced moisture sensitivity.
What manufacturing and IP barriers affect cevimeline products?
Manufacturing barriers are moderate. The active pharmaceutical ingredient is not a biologic and does not require aseptic fill-finish. The principal manufacturing issues are:
- API purity and impurity control.
- Salt-form consistency.
- Blend uniformity.
- Capsule-fill weight control.
- Lubricant optimization.
- Dissolution reproducibility.
- Moisture protection.
- Capsule-shell compatibility.
- Stability under accelerated conditions.
Excipient supply risk can affect a product even when the formulation is simple. Lactose, starch, magnesium stearate, gelatin, HPMC, and specialty taste-masking polymers are available from multiple suppliers, which reduces concentration risk. Dual sourcing and validated supplier changes can support uninterrupted commercial supply.
What licensing deals are possible for cevimeline formulations?
The most plausible licensing structures involve product and platform rights rather than rights to the basic molecule. Commercial candidates include:
- Regional rights to a generic capsule.
- Co-development of an ODT or modified-release product.
- Licensing of a taste-masking platform.
- Contract manufacturing with formulation ownership retained by the sponsor.
- Acquisition of an existing ANDA or 505(b)(2) application.
- Out-licensing of a formulation patent to a specialty-generic company.
A licensing transaction would likely depend on market exclusivity, formulation differentiation, development stage, and the ability to secure reimbursement. Rights to an unprotected conventional capsule would generally command less value than rights to a clinically differentiated formulation.
What revenue exposure exists for cevimeline manufacturers?
Revenue exposure is concentrated in the reference product and any products that achieve preferred generic status. The market is constrained by:
- A single principal approved indication in the United States.
- Specialist prescribing.
- Generic substitution.
- Competition from pilocarpine.
- Nonprescription saliva substitutes.
- Side-effect-related discontinuation.
- Limited opportunities for price expansion without formulation innovation.
The strongest revenue strategy is not a high-price conventional generic. It is a differentiated product that improves convenience, tolerability, or administration for patients with severe oral dryness.
Key Takeaways
- Cevimeline hydrochloride is an FDA-approved, mature small-molecule drug with high conventional generic-entry risk.
- The immediate-release capsule is technically simple and offers limited protection from ordinary excipient substitutions.
- The strongest excipient opportunities are lactose-free capsules, HPMC shells, orally disintegrating tablets, taste-masked systems, and modified-release formulations.
- A three-times-daily dosing schedule creates the clearest commercial rationale for sustained-release development.
- A 505(b)(2) strategy is more suitable than an ANDA when the product changes route, release profile, strength, or clinical use.
- Patent value will depend on specific composition and performance claims, not on routine filler substitution.
- Commercial opportunity is concentrated in formulation differentiation, supply reliability, and specialty distribution.
- Cevimeline should be compared primarily with pilocarpine, saliva substitutes, and other symptomatic treatments for Sjögren's syndrome.
FAQs
Can cevimeline hydrochloride be formulated as a lactose-free product?
Yes. Lactose can generally be replaced with mannitol, microcrystalline cellulose, starch, or another suitable diluent, provided the product meets dissolution, stability, content-uniformity, and bioequivalence requirements.
Is an orally disintegrating cevimeline product commercially attractive?
Potentially. An ODT could address swallowing difficulty and eliminate the need for water, but taste masking, dose accuracy, oral tolerability, and the risk of inappropriate repeat dosing would require careful development.
Would an HPMC capsule create meaningful patent protection?
Not by itself. An HPMC shell is a commercially useful excipient choice, but broad protection based only on capsule-shell substitution would likely be limited. Stronger claims would require a defined formulation and a demonstrated stability or performance benefit.
Could a modified-release cevimeline product qualify for market exclusivity?
Possibly, depending on the regulatory pathway and supporting data. A modified-release product may qualify for certain statutory protections and formulation patents, but exclusivity would not arise automatically from changing the release profile.
What is the main commercial risk for a cevimeline reformulation?
The main risk is insufficient differentiation from inexpensive immediate-release generics. A reformulated product must deliver a measurable adherence, tolerability, administration, or supply advantage to support premium pricing.
References
- U.S. Food and Drug Administration. (2000). Evoxac (cevimeline hydrochloride) prescribing information.
- U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- DailyMed. (n.d.). Cevimeline hydrochloride capsule: Prescribing information and inactive ingredients. U.S. National Library of Medicine.
- U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format.
- U.S. Food and Drug Administration. (2024). Applications covered by Section 505(b)(2).
